Investigadores
Inicio
Investigadores
Instituto de Investigación Biomédica Bellvitge (IDIBELL). Barcelona.
Terapia Génica
Juan José Rojas Expósito
Investigador colaborador
Grupo de Investigación: Instituto de Investigación Biomédica Bellvitge (IDIBELL). Barcelona.
Bespalov D., Pino D., Vidal-Guirao S., Franquesa J., Lopez-Ramajo D., Filgaira I., Wan L., O’Sullivan P.A., Ley S.C., Forcales S.V., Rojas J.J., Izquierdo-Serra M., Soler C., Manils J.. Bioinformatic analysis of molecular characteristics and oncogenic features of CARD14 in human cancer. Scientific Reports. December 2024. DOI: 10.1038/s41598-024-74565-4.
Impacto: 3.8. Cuartil: Q1
Pardo-Cea M.A., Farré X., Esteve A., Palade J., Espín R., Mateo F., Alsop E., Alorda M., Blay N., Baiges A., Shabbir A., Comellas F., Gómez A., Arnan M., Teulé A., Salinas M., Berrocal L., Brunet J., Rofes P., Lázaro C., Conesa M., Rojas J.J., Velten L., Fendler W., Smyczynska U., Chowdhury D., Zeng Y., He H.H., Li R., Van Keuren-Jensen K., de Cid R., Pujana M.A.. Biological basis of extensive pleiotropy between blood traits and cancer risk. Genome Medicine. December 2024. DOI: 10.1186/s13073-024-01294-8.
Impacto: 10.4. Cuartil: Q1
(1er decil)
Rojas J.J., Van Hoecke L., Conesa M., Bueno-Merino C., del Canizo A., Riederer S., Barcia M., Brosinski K., Lehmann M.H., Volz A., Saelens X., Sutter G.. A new MVA ancestor-derived oncolytic vaccinia virus induces immunogenic tumor cell death and robust antitumor immune responses. Molecular Therapy. 3 July 2024. DOI: 10.1016/j.ymthe.2024.05.014.
Impacto: 12.1. Cuartil: Q1
(1er decil)
Costa-Garcia M., Rojas J., Ramos M., Barlabé P., Calvo P., Navas J., Alemany R., Moreno R.. Oncolytic adenovirus coding for shedding-resistant MICA enhances immune responses against tumors. Cancer Immunology, Immunotherapy. January 2024. DOI: 10.1007/s00262-023-03611-3.
Impacto: 4.6. Cuartil: Q1
Langenmayer M.C., Luelf-Averhoff A.T., Marr L., Jany S., Freudenstein A., Adam-Neumair S., Tscherne A., Fux R., Rojas J.J., Blutke A., Sutter G., Volz A.. Newly Designed Poxviral Promoters to Improve Immunogenicity and Efficacy of MVA-NP Candidate Vaccines against Lethal Influenza Virus Infection in Mice. Pathogens. July 2023. DOI: 10.3390/pathogens12070867.
Impacto: 3.3. Cuartil: Q2
Riederer S., del Canizo A., Navas J., Peter M.G., Link E.K., Sutter G., Rojas J.J.. Improving poxvirus-mediated antitumor immune responses by deleting viral cGAMP-specific nuclease. Cancer Gene Therapy. July 2023. DOI: 10.1038/s41417-023-00610-5.
Impacto: 4.8. Cuartil: Q1
Riederer S., Fux R., Lehmann M.H., Volz A., Sutter G., Rojas J.J.. Activation of interferon regulatory factor 3 by replication-competent vaccinia viruses improves antitumor efficacy mediated by T cell responses. Molecular Therapy Oncolytics. 24 September 2021. DOI: 10.1016/j.omto.2021.06.001.
Impacto: 6.311. Cuartil: Q2
Van Hoecke L., Riederer S., Saelens X., Sutter G., Rojas J.J.. Recombinant viruses delivering the necroptosis mediator MLKL induce a potent antitumor immunity in mice. OncoImmunology. 1 January 2020. DOI: 10.1080/2162402X.2020.1802968.
Impacto: 8.11. Cuartil: Q1
Hou W., Sampath P., Rojas J.J., Thorne S.H.. Oncolytic Virus-Mediated Targeting of PGE<inf>2</inf> in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy. Cancer Cell. 11 July 2016. DOI: 10.1016/j.ccell.2016.05.012.
Impacto: 27.407. Cuartil: Q1
(1er decil)
Rojas J.J., Sampath P., Bonilla B., Ashley A., Hou W., Byrd D., Thorne S.H.. Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies. Cell Reports. 12 April 2016. DOI: 10.1016/j.celrep.2016.03.017.
Impacto: 8.282. Cuartil: Q1
Rojas J.J., Sampath P., Hou W., Thorne S.H.. Defining effective combinations of immune checkpoint blockade and oncolytic virotherapy. Clinical Cancer Research. 15 December 2015. DOI: 10.1158/1078-0432.CCR-14-2009.
Impacto: 8.738. Cuartil: Q1
(1er decil)
Zhang M., Chakraborty S.K., Sampath P., Rojas J.J., Hou W., Saurabh S., Thorne S.H., Bruchez M.P., Waggoner A.S.. Fluoromodule-based reporter/probes designed for in vivo fluorescence imaging. Journal of Clinical Investigation. 1 October 2015. DOI: 10.1172/JCI81086.
Impacto: 12.575. Cuartil: Q1
(1er decil)
Rodríguez-García A., Giménez-Alejandre M., Rojas J.J., Moreno R., Bazan-Peregrino M., Cascalló M., Ramon A.. Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. Clinical Cancer Research. 15 March 2015. DOI: 10.1158/1078-0432.CCR-14-2213.
Impacto: 8.738. Cuartil: Q1
(1er decil)
Hou W., Chen H., Rojas J., Sampath P., H. Thorne S.. Oncolytic vaccinia virus demonstrates antiangiogenic effects mediated by targeting of VEGF. International Journal of Cancer. 1 September 2014. DOI: 10.1002/ijc.28747.
Impacto: 5.085. Cuartil: Q1
Rojas J.J., Thorne S.H.. Imaging of Oncolytic Virus Gene Expression. Gene Therapy of Cancer: Translational Approaches from Preclinical Studies to Clinical Implementation: Third Edition. August 2013. DOI: 10.1016/B978-0-12-394295-1.00031-7.
Guedan S., Grases D., Rojas J.J., Gros A., Vilardell F., Vile R., Mercade E., Cascallo M., Alemany R.. GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Therapy. November 2012. DOI: 10.1038/gt.2011.184.
Impacto: 4.321. Cuartil: Q1
Rojas J.J., Thorne S.H.. Theranostic potential of oncolytic vaccinia virus. Theranostics. 2012. DOI: 10.7150/thno.3724.
Impacto: 7.806. Cuartil: Q1
(1er decil)
Rojas J.J., Gimenez-Alejandre M., Gil-Hoyos R., Cascallo M., Alemany R.. Improved systemic antitumor therapy with oncolytic adenoviruses by replacing the fiber shaft HSG-binding domain with RGD. Gene Therapy. April 2012. DOI: 10.1038/gt.2011.106.
Impacto: 4.321. Cuartil: Q1
Nokisalmi P., Pesonen S., Escutenaire S., Särkioja M., Raki M., Cerullo V., Laasonen L., Alemany R., Rojas J., Cascallo M., Guse K., Rajecki M., Kangasniemi L., Haavisto E., Karioja-Kallio A., Hannuksela P., Oksanen M., Kanerva A., Joensuu T., Ahtiainen L., Hemminki A.. Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clinical Cancer Research. 1 June 2010. DOI: 10.1158/1078-0432.CCR-09-3167.
Impacto: 7.338. Cuartil: Q1
(1er decil)
Rojas J.J., Guedan S., Searle P.F., Martinez-Quintanilla J., Gil-Hoyos R., Alcayaga-Miranda F., Cascallo M., Alemany R.. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses. Molecular Therapy. November 2010. DOI: 10.1038/mt.2010.173.
Impacto: 7.149. Cuartil: Q1
(1er decil)
Alcayaga-Miranda F., Cascallo M., Rojas J., Pastor J., Alemany R.. Osteosarcoma cells as carriers to allow antitumor activity of canine oncolytic adenovirus in the presence of neutralizing antibodies. Cancer Gene Therapy. November 2010. DOI: 10.1038/cgt.2010.36.
Impacto: 3.744. Cuartil: Q1
Guedan S., Rojas J., Gros A., Mercade E., Cascallo M., Alemany R.. Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth. Molecular Therapy. July 2010. DOI: 10.1038/mt.2010.79.
Impacto: 7.149. Cuartil: Q1
(1er decil)
Gros A., Puig C., Guedan S., Rojas J.J., Alemany R., Cascallo M.. Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses. Molecular Therapy. May 2010. DOI: 10.1038/mt.2010.22.
Impacto: 7.149. Cuartil: Q1
(1er decil)
Rojas J., Cascallo M., Guedan S., Gros A., Martinez-Quintanilla J., Hemminki A., Alemany R.. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Therapy. 3 December 2009. DOI: 10.1038/gt.2009.103.
Impacto: 4.745. Cuartil: Q1
(1er decil)
Cascallo M., Alonso M.M., Rojas J.J., Perez-Gimenez A., Fueyo J., Alemany R.. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway. Molecular Therapy. September 2007. DOI: 10.1038/sj.mt.6300239.
Impacto: 5.862. Cuartil: N/D